Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accumulated Expenses (2016 - 2018)

Historic Accumulated Expenses for Viking Therapeutics (VKTX) over the last 5 years, with Q1 2018 value amounting to $34000.0.

  • Viking Therapeutics' Accumulated Expenses changed N/A to $34000.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $34000.0, marking a year-over-year change of. This contributed to the annual value of $22000.0 for FY2017, which is 3695.19% down from last year.
  • As of Q1 2018, Viking Therapeutics' Accumulated Expenses stood at $34000.0.
  • Viking Therapeutics' Accumulated Expenses' 5-year high stood at $183611.0 during Q4 2015, with a 5-year trough of $9982.0 in Q3 2017.
  • For the 5-year period, Viking Therapeutics' Accumulated Expenses averaged around $70009.8, with its median value being $47113.5 (2016).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 9136.74% in 2016, then soared by 46750.84% in 2017.
  • Over the past 5 years, Viking Therapeutics' Accumulated Expenses (Quarter) stood at $77222.0 in 2014, then skyrocketed by 137.77% to $183611.0 in 2015, then crashed by 81.0% to $34894.0 in 2016, then plummeted by 36.95% to $22000.0 in 2017, then skyrocketed by 54.55% to $34000.0 in 2018.
  • Its Accumulated Expenses was $34000.0 in Q1 2018, compared to $22000.0 in Q4 2017 and $9982.0 in Q3 2017.